What Is The Current and Historic Market Size Analysis Of The Peripheral Vasodilator Drugs Market?
The peripheral vasodilator drugs market has seen considerable growth due to a variety of factors.
• The peripheral vasodilator drugs market has shown strong growth in recent years. It will grow from $6.27 billion in 2024 to $6.67 billion in 2025, at a compound annual growth rate (CAGR) of 6.3%.
This growth is due to the trend towards less invasive surgical methods, the demand for minimally invasive structural heart devices, ongoing training programs for healthcare professionals, rising healthcare expenditures, and growing patient preference for non-surgical or minimally invasive treatments.
What Are The Predictions for The Peripheral Vasodilator Drugs Market in the Coming Years?
The peripheral vasodilator drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The peripheral vasodilator drugs market is forecasted to grow to $8.44 billion by 2029, with a CAGR of 6.1%.
The growth is driven by an aging population, greater heart health awareness, screening programs, favorable reimbursement policies, and timely regulatory approvals. Trends include increased collaboration, real-world evidence, gene therapy, preventive interventions, and value-based healthcare.
Which Drivers Are Accelerating Growth In The Peripheral Vasodilator Drugs Market?
The peripheral vasodilator drug market is predicted to expand due to a rise in occurrences of cardiovascular diseases. Cardiovascular diseases (CVDs) are disorders that affect the heart and blood vessels, often triggered by atherosclerosis, resulting in conditions like heart attacks, strokes, hypertension, and heart failure. These diseases primarily emerge due to sedentary lifestyles, unhealthy diet habits, aging populations, increasing obesity levels, and related health issues such as diabetes and hypertension. Peripheral vasodilators are beneficial in treating cardiovascular diseases as they enhance blood flow, lower blood pressure, lessen the heart’s workload, and help relieve symptoms of conditions like peripheral arterial disease. For instance, the Australian Institute of Health and Welfare, in June 2024, estimated that doctor-certified deaths from coronary heart disease (CHD) escalated to 14,100 in 2021 and further rose to 14,900 in 2022. Hence, the surge in cardiovascular diseases is fuelling the development of the peripheral vasodilator drug market.
What Are The Core Segments Of The Global Peripheral Vasodilator Drugs Market?
The peripheral vasodilator drugs market covered in this report is segmented –
1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types
2) By Indication: Hypertension, Angina, Heart Failure, Other Indications
3) By Application: Hospital, Retail Pharmacies, Other Applications
Subsegments:
1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
2) By Direct-Acting Vasodilators: Hydralazine, Minoxidil, Nitroprusside
3) By Alpha-Adrenergic Blockers: Prazosin, Doxazosin, Terazosin
4) By Potassium Channel Activators: Nicorandil, Diazoxide
5) By Nitrates: Nitroglycerin, Isosorbide Dinitrate, Isosorbide Mononitrate
6) By Other Types: Phosphodiesterase Inhibitors, Endothelin Receptor Antagonists
Pre-Book The Peripheral Vasodilator Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Peripheral Vasodilator Drugs Market?
Firms in the peripheral vasodilator drugs market, primarily geared towards maximizing treatment results and gaining a foothold in cardiovascular therapeutic markets, are now focusing on the creation of triple-drug combination therapies. This is a specific antihypertensive FDC targeting patients whose blood pressure has not been effectively controlled using dual-drug methods or who find it challenging to endure diuretic-based combinations. In August 2023, Ajanta Pharma Limited, a pharmaceutical organization from India with a specialization in cardiology, launched Met XL AMT, a groundbreaking three-drug blend for managing hypertension in Indian patients. This fixed-dose combination (FDC) includes three antihypertensives, specifically Telmisartan, Amlodipine, and Metoprolol. These work in unison to decrease blood pressure by causing blood vessels to relax, a signature attribute of peripheral vasodilators. This drug, which has received the green light from DCGI to manage uncontrolled hypertension along with stable coronary artery disease, is the first-ever fixed-dose combination (FDC) in the world of metoprolol succinate (extended-release) at 50 mg, amlodipine at 5 mg, and telmisartan at 40 mg.
Who Are the Key Players In The Peripheral Vasodilator Drugs Market?
Major companies operating in the peripheral vasodilator drugs market are:
• Pfizer Inc.
• Bayer AG
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GSK plc
• Takeda Pharmaceutical Company
• Gilead Sciences Inc
• Amgen Inc
• Boehringer Ingelheim International GmbH
• Merck & Co
• Viatris Inc.
• Baxter
• Teva Pharmaceutical Industries
• Astellas Pharma
• Daiichi Sankyo Company
• Limited
• Sun Pharmaceutical Industries
• Mitsubishi Tanabe Pharma
• Cipla Limited
• Hikma Pharmaceuticals
• Lupin Pharmaceuticals
• Glenmark Pharmaceuticals Ltd
• Torrent Pharmaceuticals
• Ipca Laboratories
• Alembic Pharmaceuticals
What Are The Regional Insights Into The Peripheral Vasodilator Drugs Market?
North America was the largest region in the peripheral vasodilator drugs market in 2024. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
